関: metildigoxin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/05/28 11:39:01」(JST)

wiki en

Metildigoxin (INN, or medigoxin BAN, or methyldigoxin) is a cardiac glycoside,^[1] a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). The substance is closely related to digoxin; it differs from the latter only by an O-methyl group on the terminal monosaccharide.

References

^ Hayward, R.; Greenwood, H.; Stephens, J.; Hamer, J. (1983). "Relationship between myocardial uptake and actions in heart failure of methyldigoxin". British Journal of Clinical Pharmacology. 15 (1): 41–48. doi:10.1111/j.1365-2125.1983.tb01461.x. PMC 1427830 . PMID 6849743.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

Unintentional lethal overdose with metildigoxin in a 36-week-old infant--post mortem tissue distribution of metildigoxin and its metabolites by liquid chromatography tandem mass spectrometry.

Hess C1, Brockmann C2, Doberentz E2, Madea B2, Musshoff F3.
Forensic science international.Forensic Sci Int.2014 Aug;241:e23-7. doi: 10.1016/j.forsciint.2014.05.013. Epub 2014 May 24.
A massive lethal overdose with beta-metildigoxin in a 36-week-old infant is presented. Determination of beta-metildigoxin and its metabolites digoxin, digoxigenin and digoxigenin-monodigitoxosid is achieved by a liquid chromatographic mass spectrometric (LC-MS/MS) method. Measured concentrations for
PMID 24889325

Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study.

Eyer F1, Steimer W, Müller C, Zilker T.
American journal of critical care : an official publication, American Association of Critical-Care Nurses.Am J Crit Care.2010 Jul;19(4):391-87. doi: 10.4037/ajcc2009227. Epub 2009 Oct 29.
A woman ingested 10 mg of methyldigoxin in a suicide attempt and presented 19 hours after ingestion with clinical signs of glycoside intoxication. Her serum level of digoxin was 7.4 ng/mL, and antidotal therapy with Fab antibody fragments was started. The manufacturer's recommended dosing scheme was
PMID 19875723

Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system.

Balenovic D1, Bencic ML, Udovicic M, Simonji K, Hanzevacki JS, Barisic I, Kranjcevic S, Prkacin I, Coric V, Brcic L, Coric M, Brcic I, Borovic S, Radic B, Drmic D, Vrcic H, Seiwerth S, Sikiric P.
Regulatory peptides.Regul Pept.2009 Aug 7;156(1-3):83-9. doi: 10.1016/j.regpep.2009.05.008. Epub 2009 May 22.
Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419) reversed congestive heart failure and various arrhythmias, influenced the NO-system and showed no proarrhythmic effect. In therapy analogy, we challenged rats with digitalis, to show attenuation by BPC 157 and the relation between the NO-system and
PMID 19465062

Japanese Journal

Comparison of digoxin and medigoxin in normal subjects

Br. J. Clin. Pharmacol. 6, 81-86, 1978
NAID 10011505258

Related Pictures

★リンクテーブル★

リンク元

「メジゴキシン」

Metildigoxin
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	C;
ATC code	C01AA08 (WHO);
Identifiers
	IUPAC name (3β,5β,12β)-3-{[2,6-dideoxy-4-O-methyl-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide;
Synonyms	4-[(3S,5R,8R,9S,10S,12R,13S,14S)-12,14-Dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyl-oxan-2-yl]oxy-6-methyl-oxan-2-yl]oxy-6-methyl-oxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
CAS Number	30685-43-9;
PubChem CID	443946;
ChemSpider	392000 ;
UNII	I7GG1YUC5V;
ECHA InfoCard	100.045.705
Chemical and physical data
Formula	C42H66O14
Molar mass	794.965
3D model (Jmol)	Interactive image;
	SMILES O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](OC)[C@@H](O)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6 ;
	InChI InChI=1S/C42H66O14/c1-20-37(49-6)29(43)16-35(51-20)55-39-22(3)53-36(18-31(39)45)56-38-21(2)52-34(17-30(38)44)54-25-9-11-40(4)24(14-25)7-8-27-28(40)15-32(46)41(5)26(10-12-42(27,41)48)23-13-33(47)50-19-23/h13,20-22,24-32,34-39,43-46,48H,7-12,14-19H2,1-6H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m1/s1 ; Key:IYJMSDVSVHDVGT-PEQKVOOWSA-N ;
(verify)

　　[★]

英: medigoxin
関: メチルジゴキシン

[1] Hayward, R.; Greenwood, H.; Stephens, J.; Hamer, J. (1983). "Relationship between myocardial uptake and actions in heart failure of methyldigoxin". British Journal of Clinical Pharmacology. 15 (1): 41–48. doi:10.1111/j.1365-2125.1983.tb01461.x. PMC 1427830 . PMID 6849743.

匿名

検索

案内

案内

medigoxin